PT  - JOURNAL ARTICLE
AU  - Simmons, Alison E.
AU  - Miranda, Rafael N.
AU  - Li, Michael W.Z.
AU  - Gebretekle, Gebremedhin B.
AU  - Xi, Min
AU  - Salvadori, Marina I.
AU  - Warshawsky, Bryna
AU  - Wong, Eva
AU  - Ximenes, Raphael
AU  - Andrew, Melissa K.
AU  - Wilson, Sarah
AU  - Tunis, Matthew
AU  - Tuite, Ashleigh R.
TI  - Cost-utility analysis of current COVID-19 vaccination program recommendations in Canada
AID  - 10.1101/2024.12.13.24318988
DP  - 2024 Jan 01
TA  - medRxiv
PG  - 2024.12.13.24318988
4099  - http://medrxiv.org/content/early/2024/12/14/2024.12.13.24318988.short
4100  - http://medrxiv.org/content/early/2024/12/14/2024.12.13.24318988.full
AB  - Background As COVID-19 becomes established as an endemic disease with widespread population immunity, there is uncertainty about the economic benefit of ongoing COVID-19 vaccination programs. We assessed the cost-effectiveness of a COVID-19 vaccination program similar to current Canadian recommendations, modelled as annual vaccination for people aged less than 65 years with chronic medical conditions and biannual vaccination for adults aged 65 years and older.Methods Using a static individual-based model of medically attended COVID-19 in a population of 1 million people, we estimated costs (in 2023 Canadian dollars), quality-adjusted life years (QALYs), and incremental cost-effectiveness ratios (ICERs). We used health system and societal perspectives and a 1.5% discount rate. Parameters were based on recent COVID-19 epidemiology, vaccine characteristics, and costs.Results Between July 2024 and September 2025, a program similar to current Canadian recommendations was estimated to avert 3.1% (95% credible interval (CrI): 3.0 to 3.2%) of outpatient cases, 8.8% (95% CrI: 7.3 to 10.4%) of inpatient cases, 3.6% (95% CrI: 2.8 to 4.3%) of PCC cases, and 9.4% (95% CrI: 5.6 to 13.8%) of deaths compared to no vaccination. The number needed to vaccinate to prevent one hospitalization and one death was 1,121 (95% CrI: 941 to 1,357) and 8,656 (95% CrI: 5,848 to 14,915), respectively. For the health system perspective, the program would cost an additional $4.695 million but result in 221.17 QALYs gained, leading to an ICER of $21,227 per QALY compared to no vaccination. Vaccine price influenced cost-effectiveness, with higher prices reducing the likelihood the program met common cost-effectiveness thresholds.Conclusions A program similar to current COVID-19 recommendations in Canada is likely effective and cost-effective compared to no vaccination. However, unlike some other research studies, alternate vaccination strategies that may offer better value for money were not evaluated.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present work are contained in the manuscript.